Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1566492 | 1.00 | SLC6A3 (0.57) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL11001290 | 0.84 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL28444472 | 0.83 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL28897035 | 0.82 | TDP1 (0.43) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1626214 | 0.82 | SLC6A3 (0.57) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL5487986 | 0.82 | SLC6A3 (0.57) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL6988620 | 0.81 | SLC6A3 (0.56) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL30522901 | 0.81 | SLC6A3 (0.56) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL9395161 | 0.81 | SLC6A3 (0.56) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL1565500 | 0.81 | SLC6A3 (0.56) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | SLC6A3 4353/4885SLC6A2 3603/4885SLC6A4 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.